Centre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Multiple Sclerosis Centre, Bajcsy-Zsilinszky Hospital, Maglódi út 89-91, Budapest, 1106, Hungary.
Ann Clin Transl Neurol. 2024 Mar;11(3):564-576. doi: 10.1002/acn3.51976. Epub 2024 Jan 11.
Methods of cognitive measurements in multiple sclerosis (MS) are not standardized. We aimed to identify the prevalence of cognitive domain-specific impairment (DSI) in MS by using subtests of the Brief Repeatable Battery of Neuropsychological Tests (BRB-N) with analyzing different cutoff values.
The systematic review and meta-analysis were registered on PROSPERO (ID: CRD42021287004). The systematic literature search was performed via PubMed, Embase, and CENTRAL on 24 October 2021. Inclusion criteria were adults of different MS subtypes (CIS, RRMS, PPMS, and SPMS) with the condition of distinct DSI measured by BRB-N. Pediatric MS, computerized versions of BRB-N, and patients receiving steroids were excluded. Primary outcome was pooled prevalence rates of impaired patients within each cutoff and MS subtype, with 95% confidence interval, I-squared statistics for heterogeneity, and chi-squared test for subgroup differences. Risk of bias was assessed using the "JBI Quality Assessment Tool for Prevalence Studies."
In 48 eligible observational studies (n = 3431 patients), the three most prevalent thresholds were the 2.0 SD and 1.5 SD below the mean of normative values, and the score below the fifth percentile of the normative values. A progressively increasing worsening of the overall DSI was observed from CIS, moving toward RRMS, PPMS, and SPMS.
Cognitive impairment is observed in all MS phenotypes, with varying degrees. Due to several potential influencing factors, our comprehensive literature review has not revealed consistent findings, and we, therefore, recommend considering a more sophisticated, "individual referencing" approach, acknowledging the diverse clinical and sociodemographic characteristics among populations and disparities in cognitive testing.
多发性硬化症(MS)的认知测量方法尚未标准化。我们旨在通过使用 BRB-N 的子测试来识别 MS 中认知领域特异性损伤(DSI)的患病率,并分析不同的截止值。
系统评价和荟萃分析在 PROSPERO 上进行(ID:CRD42021287004)。系统文献检索于 2021 年 10 月 24 日通过 PubMed、Embase 和 CENTRAL 进行。纳入标准为不同 MS 亚型(CIS、RRMS、PPMS 和 SPMS)的成年人,其 BRB-N 测定的条件为明确的 DSI。排除小儿 MS、BRB-N 的计算机化版本和接受类固醇治疗的患者。主要结局是每个截止值和 MS 亚型内受损患者的汇总患病率,包括 95%置信区间、异质性 I 平方统计量和亚组差异的卡方检验。使用“JBI 患病率研究质量评估工具”评估偏倚风险。
在 48 项符合条件的观察性研究(n=3431 名患者)中,最常用的三个阈值是平均值的 2.0 SD 和 1.5 SD 以下,以及正常值第五个百分位数以下的分数。从 CIS 到 RRMS、PPMS 和 SPMS,观察到整体 DSI 逐渐恶化。
认知障碍在所有 MS 表型中均有发生,程度不同。由于存在多种潜在的影响因素,我们的综合文献综述没有发现一致的结果,因此我们建议考虑一种更复杂的“个体参考”方法,承认人群之间存在不同的临床和社会人口统计学特征以及认知测试中的差异。